{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:03:22Z","timestamp":1774314202711,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study evaluated data from six Swedish national registries to fill current evidence gaps on the epidemiology, clinical burden, and overall survival (OS) associated with light\u2010chain (AL) amyloidosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients newly diagnosed with AL amyloidosis were identified using six linked Swedish nationwide population\u2010based registers. For each case, individuals from the general population were selected and matched with a maximum ratio of 1:5 based on age, sex, calendar year, and county.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>846 patients newly diagnosed with AL amyloidosis and 4227 demographically matched individuals were identified. From 2011 to 2019, annual AL amyloidosis incidence increased from 10.5 to 15.1 cases per million. At baseline, patients with AL amyloidosis had a significantly higher disease burden including higher rates of cardiac and renal failure relative to the comparison group. Among patients with AL amyloidosis, 21.5% had incident heart failure and 17.1% had incident renal failure after initial diagnosis. Median OS for patients with AL amyloidosis was 56\u2009months versus not reached in the matched general population comparison group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The incidence of newly diagnosed AL amyloidosis in Sweden increased over time with AL amyloidosis being associated with a higher risk of cardiac\/renal failure and all\u2010cause mortality compared with the general population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14063","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T06:45:03Z","timestamp":1691045103000},"page":"697-705","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Epidemiology and clinical outcomes of light\u2010chain amyloidosis in Sweden: A nationwide population\u2010based study"],"prefix":"10.1111","volume":"111","author":[{"given":"Ulf\u2010Henrik","family":"Mellqvist","sequence":"first","affiliation":[{"name":"Section of Hematology and Coagulation, Department of Medicine Sahlgrenska University Hospital  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-1035","authenticated-orcid":false,"given":"Qian","family":"Cai","sequence":"additional","affiliation":[{"name":"Janssen Global Services  Titusville New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-1293","authenticated-orcid":false,"given":"Laura L.","family":"Hester","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Horsham Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gr\u00f6vdal","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag  Solna Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"B\u00f6rsum","sequence":"additional","affiliation":[{"name":"SDS Life Science  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-7063","authenticated-orcid":false,"given":"Iffat","family":"Rahman","sequence":"additional","affiliation":[{"name":"SDS Life Science  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-5388","authenticated-orcid":false,"given":"Eric M.","family":"Ammann","sequence":"additional","affiliation":[{"name":"Janssen Global Services  Raritan New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-4548","authenticated-orcid":false,"given":"Markus","family":"Hansson","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sahlgrenska Academy G\u00f6teborg University and Sahlgrenska University Hospital  Gothenburg Sweden"},{"name":"Department of Hematology Sk\u00e5ne University Hospital  Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-54"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5493"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0034-3"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4385"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.004"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006913"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.09.003"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.041"},{"issue":"1","key":"e_1_2_12_10_1","first-page":"5577","article-title":"Incidence and prevalence of light chain amyloidosis: a population\u2010based study","volume":"130","author":"Duhamel S","year":"2017","journal-title":"Blood"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016402"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02414-6"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-974"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4448.4448"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00494.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2017.1407039"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0316-1"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00511-8"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-016-0117-y"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001755"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751628"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.07.007"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13679"},{"key":"e_1_2_12_25_1","first-page":"1262","article-title":"Understanding real\u2010world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: a population\u2010based cohort study","volume":"1","author":"Jimenez\u2010Zepeda V","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-473066"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508287"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310704"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140708"},{"key":"e_1_2_12_30_1","unstructured":"FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis. Accessed September 6 2022.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010darzalex\u2010faspro\u2010newly\u2010diagnosed\u2010light\u2010chain\u2010amyloidosis"},{"key":"e_1_2_12_31_1","unstructured":"EMA recommends extension of indications for daratumumab. Accessed September 6 2022.https:\/\/www.esmo.org\/oncology\u2010news\/ema\u2010recommends\u2010extension\u2010of\u2010indications\u2010for\u2010daratumumab#:~:text=On%2020%20May%202021%2C%20the medicinal%20product%20daratumumab%20(Darzalex)"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00529-w"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T08:48:11Z","timestamp":1704530891000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/ejh.14063"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14063","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"2023-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}